Central Foveal Thickness Cut-off Value Identified for Corticosteroid Treatment in Intermediate Uveitis

AUGUST 16, 2016
Ellen Kurek
At baseline, the investigators found significant differences in mean CFT between patients treated with systemic corticosteroids and untreated patients (p = 0.0005) as well as between untreated patients and healthy volunteers (p < 0.001). They also found a strong correlation between BCVA and CFT at baseline (r = 0.743, p < 0.0001).

However, after 6 months, the difference in CFT between the two patient subgroups was no longer significant (p = 0.699), although BCVA was worse in those receiving systemic corticosteroid treatment. No statistically significant difference in BCVA was found between the subgroup of untreated patients and the group of healthy volunteers either at baseline or after 6 months.

In the treated patients who were available for the 6-month follow-up visit, mean CFT decreased to a significant degree from 325 μm ± 122 μm to 209 μm ± 86 μm (n = 25, p = 0.0004), and mean BCVA improved slightly but significantly from 0.222 ± 0.249 to 0.087 ± 0.125 (p = 0.0075). However, in untreated patients, neither CFT nor BCVA changed to a statistically significant degree from baseline after 6 months. As a result of these findings, the investigators concluded that, in mildly inflamed eyes with IU, subclinical retinal thickening can occur without affecting visual function.

In a post hoc statistical analysis, the CFT cut-off value for initiating mic corticosteroid treatment in patients with IU was determined to be 215.5 μm. The sensitivity of this value was found to be 62.5%, and its specificity was found to be 96.4%. 

Related Coverage >>>
Copyright© MD Magazine 2006-2020 Intellisphere, LLC. All Rights Reserved.